FDA
-
-
-
-
-
-
-
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
-
-
-
-
-
-
-
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Socie
-
-
-
-
-
-
-
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924
-
-
-
-
-
-
-
Aileron Therapeutics Reports Second Quarter 2019 Financial Results
-
-
-
-
-
-
-
Aileron Therapeutics Reports Third Quarter 2017 Financial Results
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

